Breast cancer chemoprevention

Main Article Content

Ivana Sestak (1*), Jack Cuzick (2)

1 Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
2 Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
(*) Corresponding Author:
Ivana Sestak
ivana.sestak@cancer.org.uk

Abstract

Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced by at least 50% with prophylactic agents. The current challenge is to find new agents which achieve this or better efficacy, but with fewer side effects. Recent results indicate that the SERM raloxifene has similar efficacy to tamoxifen, but leads to fewer endometrial cancers, gynecological symptoms, and thromboembolic events. Results for contralateral tumors in adjuvant trials suggest that aromatase inhibitors may be able to prevent up to 70%–80% of ER-positive breast cancers, and this is currently being investigated in two large prevention trials, one using anastrozole (IBIS-II) and the other exemestane (MAP.3). New agents are needed for receptor negative breast cancer and several possibilities are currently under investigation.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Sestak, I., & Cuzick, J. (2011). Breast cancer chemoprevention. Oncology Reviews, 2(4), 223-228. https://doi.org/10.4081/oncol.2008.223